Company Monitoring Page for AbbVie

latest headlines for company on cafepharma

AbbVie’s top execs paint a rosy pic of the mega-blockbuster future looming for Humira and PhIII drugs
Endpoints
Fri, 09/22/17 - 09:19 am
Tags:
AbbVie, Humira, Rick Gonzalez
AbbVie, Roche to seek broader market for leukemia drug after trial success
BioPharma Dive
Tue, 09/19/17 - 10:23 pm
Tags:
AbbVie, Roche, clinical trials, Venclexta, Rituxan, chronic lymphocytic leukemia
Which of These 5 Will Be the Best-Selling Drug Worldwide in 2020?
Motley Fool
Sat, 09/16/17 - 12:01 pm
Tags:
AbbVie, Humira, Celgene, Revlimid, Bristol-Myers Squibb, Opdivo, Merck, Keytruda, Biogen, aducanumab
AbbVie keen on JAK inhibitor despite safety concerns
BioPharma Dive
Tue, 09/12/17 - 04:22 pm
Tags:
AbbVie, JAK inhibitors, Upadacitinib, ABT-494, rheumatoid arthritis
AbbVie and Pfizer hover at top, J&J Stelara surges in August TV pharma ad spend
Fierce Pharma
Mon, 09/11/17 - 09:06 pm
Tags:
AbbVie, Pfizer, JNJ, drug ads, television ads
AbbVie reports two patient deaths in rheumatoid arthritis study
Yahoo/Reuters
Mon, 09/11/17 - 09:25 am
Tags:
AbbVie, clinical trials, rheumatoid arthritis, Upadacitinib, ABT-494
AbbVie preps JAK atopic dermatitis candidate for phase 3
Fierce Biotech
Sun, 09/10/17 - 11:56 am
Tags:
AbbVie, JAK inhibitors, clinical trials, atopic dermatitis, Upadacitinib, Sanofi, Regeneron, Dupixent
This Shield of Patents Protects the World’s Best-Selling Drug
Bloomberg
Fri, 09/8/17 - 09:25 am
Tags:
patents, AbbVie, Humira
AbbVie adds more stellar data on ABT-494 — this time for atopic dermatitis
Endpoints
Thu, 09/7/17 - 09:46 am
Tags:
AbbVie, ABT-494, atopic dermatitis, Upadacitinib
Infographic | The leaders of the global hepatitis-C market
Medical Marketing and Media
Thu, 08/31/17 - 09:27 am
Tags:
hepatitis C, Gilead Sciences, Merck, AbbVie, Bristol-Myers Squibb
Pharma Stocks That Could Move On New Data
Barron's
Sat, 08/26/17 - 07:36 pm
Tags:
pharma stocks, AbbVie, Bayer, Novartis, Bristol-Myers Squibb, Eli Lilly, European Society of Cardiology
Biogen, Samsung Humira copy wins EU approval
Fierce Pharma
Fri, 08/25/17 - 09:52 am
Tags:
Biogen, Samsung Bioepis, Europe, Humira, AbbVie, Imraldi, biosimilars
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
Thu, 08/17/17 - 10:36 am
Tags:
patents, AbbVie, Humira, Pfizer, Lipitor, Norvasc, GSK, Advair, Sanofi, Lantus, JNJ, Remicade, AstraZeneca, Crestor, Nexium, Amgen, Neulasta, Novartis, Diovan
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
Thu, 08/10/17 - 06:58 pm
Tags:
pharma stocks, Merck, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, GSK, Roche, Sanofi, Bayer, Novo Nordisk, Celgene, Biogen, AstraZeneca
AbbVie’s new, cheaper hepatitis C drug could launch the drug world’s own Hunger Games
Marketwatch
Sun, 08/6/17 - 09:48 pm
Tags:
AbbVie, hepatitis C, Mavyret, Gilead Sciences, Merck
Is AbbVie About to Deliver a Blow to Gilead Sciences' Guidance?
Motley Fool
Sat, 08/5/17 - 09:44 am
Tags:
AbbVie, Gilead Sciences, hepatitis C, Mavyret
AbbVie's new pan-genotypic hepatitis C drug Mavyret deeply underprices the competition
Fierce Pharma
Fri, 08/4/17 - 11:32 am
Tags:
AbbVie, hepatitis C, Mavyret, drug pricing
J&J, AbbVie's Imbruvica breaks out of blood-cancer corner with new graft-versus-host approval
Fierce Pharma
Wed, 08/2/17 - 09:33 pm
Tags:
JNJ, AbbVie, Imbruvica, graft vs host disease, FDA
AbbVie confident in strategy as Humira mints money
BioPharma Dive
Sat, 07/29/17 - 09:44 am
Tags:
AbbVie, Humira
AbbVie scores surprisingly good Q2 results but pipeline worries persist
Fierce Pharma
Fri, 07/28/17 - 10:42 pm
Tags:
AbbVie, earnings

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.